Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Slashes Value By 70% Following Less-Than-Stellar Clinical Results
What is worse than having to cease a clinical study at the end of phase one? Well, having to end it at phase two and leave stockholders incandescent with rage. Unless you have not...